Literature DB >> 15620830

Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.

José Manuel Querol-Ribelles1, José María Tenías, José Manuel Querol-Borrás, Teodoro Labrador, Angel Nieto, Damiana González-Granda, Isidoro Martínez.   

Abstract

Consecutive adult patients admitted to the hospital with community-acquired pneumonia from January 2000 to September 2003 were included in this prospective observational cohort study. A total of 459 patients, 259 treated with levofloxacin in single drug therapy at a dose of 500 mg once a day and 209 with the combination of ceftriaxone plus clarithromycin at a dose of 2 g once a day and 500 mg every 12 h, respectively, were included. The hospital admission decision was made using a clinical guideline based on the Pneumonia Severity Index (PSI). Fifteen (6%) patients died in the group treated with levofloxacin in single drug therapy and 25 (12%) in the group treated with ceftriaxone plus clarithromycin (P = 0.024). The mortality differences between both treatment groups, adjusted by the PSI score, show an OR of 0.39 (95% CI 0.17-0.87). There were no statistically significant differences between the duration of treatments or hospital stay. These data suggest that levofloxacin as single drug therapy is more effective than the combination of ceftriaxone plus clarithromycin in the treatment of moderate to severe pneumonia that requires hospitalization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15620830     DOI: 10.1016/j.ijantimicag.2004.07.013

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  12 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

2.  What Is New in Antibiotic Therapy in Community-Acquired Pneumonia? An Evidence-Based Approach Focusing on Combined Therapy.

Authors:  Simone Gattarello
Journal:  Curr Infect Dis Rep       Date:  2015-10       Impact factor: 3.725

3.  Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.

Authors:  Thomas P Lodise; Andrea Kwa; Leon Cosler; Reetu Gupta; Raymond P Smith
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

Review 4.  Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.

Authors:  Benjamin J Epstein; John G Gums
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis.

Authors:  M H Rozenbaum; P Pechlivanoglou; T S van der Werf; J R Lo-Ten-Foe; M J Postma; E Hak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-12-14       Impact factor: 3.267

6.  Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.

Authors:  Konstantinos Z Vardakas; Ilias I Siempos; Alexandros Grammatikos; Zoe Athanassa; Ioanna P Korbila; Matthew E Falagas
Journal:  CMAJ       Date:  2008-12-02       Impact factor: 8.262

Review 7.  Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies.

Authors:  Vicente F Corrales-Medina; Kathryn N Suh; Gregory Rose; Julio A Chirinos; Steve Doucette; D William Cameron; Dean A Fergusson
Journal:  PLoS Med       Date:  2011-06-28       Impact factor: 11.069

8.  High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study.

Authors:  Jin Hwa Lee; Seo Woo Kim; Ji Hye Kim; Yon Ju Ryu; Jung Hyun Chang
Journal:  Clin Drug Investig       Date:  2012-09-01       Impact factor: 3.580

9.  Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis.

Authors:  Annie S Jasper; Jackson S Musuuza; Jessica S Tischendorf; Vanessa W Stevens; Shantini D Gamage; Fauzia Osman; Nasia Safdar
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 20.999

10.  Comparative Outcome Analysis of Penicillin-Based Versus Fluoroquinolone-Based Antibiotic Therapy for Community-Acquired Pneumonia: A Nationwide Population-Based Cohort Study.

Authors:  Chi-Chuan Wang; Chia-Hui Lin; Kuan-Yin Lin; Yu-Chung Chuang; Wang-Huei Sheng
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.